Welcome to Sana Securities! Login | Subscribe Now.

Ajanta Pharma Equity Research

HomeCompanyAjanta Pharma Equity Research

Date of Research – 12 January 2016

Price – Rs. 1,256.00

About the Company

Incorpoarated in 1973, Ajanta Pharma Limited (“Ajanta Pharma” or the “Company”) is a specialty pharmaceutical company engaged in development, manufacture and marketing of quality finished dosages in domestic and international markets. Ajanta Pharma operates with 5 state-of-the art manufacturing facilities. The Company focus on commercializing generic products and combination products in the therapeutic areas of anti-malarial, cardiovascular, dermatology, male erectile dysfunction, musculoskeletal, and ophthalmology. The Company has extensive presence in many countries in Asia, Africa and Latin America with customized product portfolio to suit the needs of each country. Having successfully gone through USFDA inspection, Ajanta Pharma has started commercial operations in the U.S. market in 2013. With a portfolio of 14 ANDAs which have been filed with the US FDA, the Company look forward to the U.S. market to be their key growth driver in coming years.

Key Financial Figures

Consolidated (Rs. Cr)
Particulars FY 2013 FY 2014 FY 2015 FY 2016  FY 2017
Total Income from Operations 930.84 1,208.34 1,480.56 1,727.53 2,001.64 
Expenses 702.95 839.59 975.33 1,146.81   1,312.63  
Earnings Before Other Income, Interest, Tax and Depreciation (Operating Profit) 227.89 368.75 505.23 580.72   689.01  
Depreciation 34.17 43.88 51.64 45.06   61.21  
Finance Costs 19.13 8.73 5.92 4.89   3.49  
Other income 2.20 13.71 16.80 16.63   23.86  
Exceptional items 8.46 – 
PBT 176.79 329.85 456.01 547.40   648.17  
Tax 64.68 95.97 146.15 145.99   141.34  
PAT (before Minority Interest and share of Associates) 112.11 233.88 309.86 401.41   506.83  
Profit/ (loss) attributable to Minority Interest –  – 
Share of profit / (loss) of Associates –  – 
Consolidated Profit / (Loss) for the year 112.11 233.88 309.86 401.41   506.83  

Profitability Analysis

Consolidated (%)
Particulars FY 2013 FY 2014 FY 2015 FY 2016  FY 2017
Operating Profit Margin Ratio 24.48 30.52 34.12 33.62 34.42 
Net Profit Margin Ratio 12.04 19.36 20.93 23.24 25.32

Operating profit margin is a measurement of the proportion of a company’s revenue that is left over after paying for production costs such as raw materials, salaries and administrative costs. Net profit margin is arrived at by deducting non operating expenses such as depreciation, finance costs and taxes out of operating profit and shows what is left for the shareholders as a percentage of net sales. Together these ratios help in understanding the cost and profit structure of the firm and analysing business inefficiencies.

Key Balance Sheet Figures

Sources of Funds / Liabilities (Rs. Cr)
Particulars FY 2012 FY 2013 FY 2014 FY 2015 FY 2016
Share Capital 11.80 11.80 17.67 17.68 17.69 
Reserves & Surplus 286.23 381.63 575.64 823.41 1,154.37 
Net worth (shareholders funds) 298.03 393.43 593.31 841.09 1,172.06 
Long term borrowings 76.09 73.33 52.30 33.25 14.87 
Current liabilities 250.19 222.33 275.42 249.59 271.47 
Other long term liabilities and provisions 7.41 5.48 5.33 7.26 3.05 
Deferred Tax Liabilities 17.09 23.65 22.99 15.16 19.98 
Total Liabilities 648.81 718.22 949.35 1,146.35 1,481.43 

 

Application of Funds / Assets (Rs. Cr)
Particulars FY 2012 FY 2013 FY 2014 FY 2015 FY 2016
Fixed Assets 248.64 285.05 372.94 458.29 691.38 
Noncurrent Investments 8.47 8.46 8.46 40.04
Current assets 339.67 369.01 520.05 633.41 763.88
Long term advances and other noncurrent assets 52.03 55.70 47.90 14.61 26.17
Total assets 648.81 718.22 949.35 1,146.35 1,481.43

Efficiency Analysis

  (%)
Particulars FY 2012 FY 2013 FY 2014 FY 2015 FY 2016
ROCE 37.62 48.82 57.12 57.78 48.93 
ROE / RONW 25.93 28.50 39.42 36.84 34.25 

Return on Capital Employed (ROCE) measures a company’s profitability from its overall operations by calculating the return generated on the total capital invested in the business (i.e. equity + debt). Return on Equity (ROE) or Return on Net Worth (RONW) measures the amount of profit which the company generates on money invested by the equity shareholders. In short, ROE draws attention to the return generated by the shareholders on their investment in the business. Together these ratios can be used in comparing the profitability of the company with other companies in the same industry.

Valuation Analysis

Consolidated
Particulars FY 2013 FY 2014 FY 2015 FY 2016  FY 2017
Total Income from Operations (Rs. Cr.) 930.84 1,208.34 1,480.56 1,727.53  2,001.64 
Growth (%) 37.41 % 29.81 % 22.53 % 16.68 %  15.87 % 
PAT (Rs. Cr.) 112.11 233.88 309.86 401.41   506.83  
Growth (%) 45.09 % 108.62 % 32.49 % 29.55 %  26.26 % 
Earnings Per Share – Basic (Rs. ) 47.87 66.54 35.24 45.62  57.59 
Earning Per Share – Diluted (Rs. ) 47.87 66.42 35.20 45.61  57.58 
Price to Earnings 19.99 15.91 36.30  30.93 26.65 

Dividend History

The Company has maintained an average dividend yield of 0.79 % over the last 5 financial years.

Liquidity and Credit Analysis

Current Ratio

Higher current ratio implies healthier short term liquidity comfort level. A current ratio below 1 indicates that the company may not be able to meet its obligations in the short run. However, it is not always a matter of worry if this ratio temporarily falls below 1 as many times companies squeeze out short term cash sources to achieve a capital intensive plan with a longer term outlook. Ajanta Pharma’s average current ratio over the last 5 financial years has been 1.71 times which indicates that that the Company is comfortably placed to pay for its short term obligations.

Long Term Debt to Equity Ratio

Companies operating with high debt to equity on their balance sheets are vulnerable to economic cycles. In times of slowdown in economy, companies with high levels of debt find it increasingly difficult to service the interest on their borrowings as profit margins decline. We believe that long term debt to equity ratio higher than 0.6 – 0.8 could affect the business of a company and its results of operations.

Ajanta Pharma’s average long term debt to equity ratio over the last 5 financial years has been 0.17 times which indicates that the Company operates with low level of debt.

Interest Coverage ratio

Interest coverage ratio indicates the comfort with which the company may be able to service the interest expense (i.e. finance charges) on its outstanding debt. Higher interest coverage ratio indicates that the company can easily meet the interest expense pertaining to its debt obligations. In our view, interest coverage ratio of below 1.5 should raise doubts about the company’s ability to meet the expenses on its borrowings. Interest coverage ratio below 1 indicates that the company is just not generating enough to service its debt obligations.

Ajanta Pharma’s average interest coverage ratio over the last 5 financial years has been 30.15 times which indicates that the Company has been generating enough for the shareholders after servicing its debt obligations.

Ownership pattern

In its latest stock exchange filing dated 31 March 2017, Ajanta Pharma reported a promoter holding of 73.78 %. Large promoter holding indicates conviction and sincerity of the promoters. We believe that a greater than 35 % promoter holding offers safety to the retail investors.

At the same time, institutional holding in the Company stood at 9.66 % (FII+DII). Large institutional holding indicates the confidence of seasoned investors. At the same time, it can also lead to high volatility in the stock price as institutions buy and sell larger stakes than retail participants.

About the Author

Rajat Sharma pictureRajat Sharma is a well known stock market analyst and commentator. He has covered Indian markets for over a decade and is regarded for consistently identifying early stage investment opportunities. Attorney by qualification, Rajat has done extensive work for improving corporate governance and disclosure standards.

 

Leave a Comment